Comparative Pharmacology
Head-to-head clinical analysis: AMBODRYL versus HYDRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBODRYL versus HYDRAMINE.
AMBODRYL vs HYDRAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine (H1-receptor antagonist) with anticholinergic and sedative properties.
Antagonist of histamine H1 receptors, preventing histamine-mediated responses such as vasodilation, bronchoconstriction, and increased capillary permeability.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed, up to a maximum of 80 mg/day.
50-100 mg IV/IM every 4-6 hours, maximum 400 mg per day. Also available as 50 mg oral tablets.
None Documented
None Documented
Terminal elimination half-life 12-15 hours in adults; prolonged to 20-30 hours in hepatic impairment.
Clinical Note
moderateDiphenhydramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
Clinical Note
moderateDiphenhydramine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
Clinical Note
moderateDiphenhydramine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diphenhydramine."
Clinical Note
moderateTerminal elimination half-life 5.7 hours, range 4.2-7.7 hours; prolonged in hepatic impairment (up to 15 hours in cirrhosis)
Primarily renal (70-80% as metabolites, 20-30% unchanged); biliary/fecal excretion accounts for 15-20%.
Primarily renal (95%) as metabolites; <5% unchanged; 5% fecal
Category C
Category C
Antihistamine
Antihistamine
Diphenhydramine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diphenhydramine."